Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 132

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Epigallocatechin-3-gallate Inhibits Osteoclastogenesis by Down-Regulating c-Fos Expression and Suppressing the Nuclear Factor-κB Signal

Lee, Jong-Ho, Jin, Hexiu, Shim, Hye-Eun, Kim, Ha-Neui, Ha, Hyunil, Lee, Zang Hee·2010·Molecular Pharmacology
DOI 10.1124/mol.109.057877
Open this paper in CoChat — free account

Abstract

Epigallocatechin-3-gallate (EGCG), the major anti-inflammatory compound in green tea, has been shown to suppress osteoclast differentiation. However, the precise molecular mechanisms underlying the inhibitory action of EGCG in osteoclastogenesis and the effect of EGCG on inflammation-mediated bone destruction remain unclear. In this study, we found that EGCG inhibited osteoclast formation induced by osteoclastogenic factors in bone marrow cell-osteoblast cocultures but did not affect the ratio of receptor activator of nuclear factor kappaB (NF-kappaB) ligand (RANKL) to osteoprotegerin induced by osteoclastogenic factors in osteoblasts. We also found that EGCG inhibited osteoclast formation from bone marrow macrophages (BMMs) induced by macrophage colony-stimulating factor plus RANKL in a dose-dependent manner without cytotoxicity. Pretreatment with EGCG significantly inhibited RANKL-induced the gene expression of c-Fos and nuclear factor of activated T-cells (NFATc1), essential transcription factors for osteoclast development. EGCG suppressed RANKL-induced activation of c-Jun N-terminal protein kinase (JNK) pathway, among the three well known mitogen-activated protein kinases and also inhibited RANKL-induced phosphorylation of the NF-kappaB p65 subunit at Ser276 and NF-kappaB transcriptional activity without affecting the degradation of IkappaBalpha and NF-kappaB DNA-binding in BMMs. The inhibitory effect of EGCG on osteoclast formation was somewhat reversed by retroviral c-F…

Overview

Integrity signals

Registry

Crossref · 10.1124/mol.109.057877

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 34

  1. Ahmed, 2006, Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts, Arthritis Rheum, 54, 2393, 10.1002/art.22023 · DOI
  2. Ahmed, 2004, Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1β-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes, J Pharmacol Exp Ther, 308, 767, 10.1124/jpet.103.059220 · DOI
  3. Biskobing, 1995, Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture, J Bone Miner Res, 10, 1025, 10.1002/jbmr.5650100706 · DOI
  4. Chen, 2001, Duration of nuclear NF-kappaB action regulated by reversible acetylation, Science, 293, 1653, 10.1126/science.1062374 · DOI
  5. Darnay, 1998, Characterization of the intracellular domain of receptor activator of NF-κB (RANK).Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase, J Biol Chem, 273, 20551, 10.1074/jbc.273.32.20551 · DOI
  6. Darnay, 1999, Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif, J Biol Chem, 274, 7724, 10.1074/jbc.274.12.7724 · DOI
  7. Dong, 2008, Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms, Genes Dev, 22, 1159, 10.1101/gad.1657408 · DOI
  8. Doss, 2005, Trapping of growth factors by catechins: a possible therapeutical target for prevention of proliferative diseases, J Nutr Biochem, 16, 259, 10.1016/j.jnutbio.2004.11.003 · DOI
  9. Franzoso, 1997, Requirement for NF-kappaB in osteoclast and B-cell development, Genes Dev, 11, 3482, 10.1101/gad.11.24.3482 · DOI · Paper page
  10. Grigoriadis, 1994, c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling, Science, 266, 443, 10.1126/science.7939685 · DOI
  11. Ha, 2006, alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis, J Immunol, 176, 111, 10.4049/jimmunol.176.1.111 · DOI
  12. Ikeda, 2004, Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation, J Clin Invest, 114, 475, 10.1172/JCI200419657 · DOI · Paper page
  13. Iotsova, 1997, Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2, Nat Med, 3, 1285, 10.1038/nm1197-1285 · DOI
  14. Kobayashi, 2001, Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis, EMBO J, 20, 1271, 10.1093/emboj/20.6.1271 · DOI
  15. Lee, 2001, Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK, J Biol Chem, 276, 49343, 10.1074/jbc.M103642200 · DOI
  16. Lee, 2002, The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation, Bone, 30, 71, 10.1016/S8756-3282(01)00657-3 · DOI
  17. Lorenzo, 1998, Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy, Endocrinology, 139, 3022, 10.1210/endo.139.6.6128 · DOI · Paper page
  18. Marshall, 2004, S-nitrosylation: physiological regulation of NF-κB, Proc Natl Acad Sci U S A, 101, 8841, 10.1073/pnas.0403034101 · DOI
  19. Matsuo, 2004, Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos, J Biol Chem, 279, 26475, 10.1074/jbc.M313973200 · DOI · Paper page
  20. Murshed, 2005, Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone, Genes Dev, 19, 1093, 10.1101/gad.1276205 · DOI
  21. Nakagawa, 2002, Fenton reaction is primarily involved in a mechanism of (−)-epigallocatechin-3-gallate to induce osteoclastic cell death, Biochem Biophys Res Commun, 292, 94, 10.1006/bbrc.2002.6622 · DOI
  22. Owen, 1990, Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix, J Cell Physiol, 143, 420, 10.1002/jcp.1041430304 · DOI
  23. Ruocco, 2005, I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss, J Exp Med, 201, 1677, 10.1084/jem.20042081 · DOI · Paper page
  24. Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3 · DOI · Paper page
  25. Takatsuna, 2005, Inhibition of RANKL-induced osteoclastogenesis by (−)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1, J Bone Miner Res, 20, 653, 10.1359/JBMR.041213 · DOI
  26. Teitelbaum, 2004, RANKing c-Jun in osteoclast development, J Clin Invest, 114, 463, 10.1172/JCI200422644 · DOI
  27. Teitelbaum, 2003, Genetic regulation of osteoclast development and function, Nat Rev Genet, 4, 638, 10.1038/nrg1122 · DOI
  28. Vermeulen, 2002, Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit, Biochem Pharmacol, 64, 963, 10.1016/S0006-2952(02)01161-9 · DOI
  29. Vermeulen, 2003, Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1), EMBO J, 22, 1313, 10.1093/emboj/cdg139 · DOI
  30. Yamamoto, 2002, Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand, J Bone Miner Res, 17, 612, 10.1359/jbmr.2002.17.4.612 · DOI
  31. Yamashita, 2007, NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1, J Biol Chem, 282, 18245, 10.1074/jbc.M610701200 · DOI
  32. Yun, 2004, Inhibitory effects of green tea polyphenol (−)-epigallocatechin gallate on the expression of matrix metalloproteinase-9 and on the formation of osteoclasts, J Periodontal Res, 39, 300, 10.1111/j.1600-0765.2004.00743.x · DOI
  33. Zhong, 2002, The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1, Mol Cell, 9, 625, 10.1016/S1097-2765(02)00477-X · DOI
  34. Zhong, 1998, Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300, Mol Cell, 1, 661, 10.1016/S1097-2765(00)80066-0 · DOI · Paper page

Cited by

See all 132

Metadata

Authors
Lee, J.-H., Jin, H., Shim, H.-E., Kim, H.-N., Ha, H., & Lee, Z. H.
Venue
Molecular Pharmacology
Publisher
Elsevier BV
Published
2010-01
Volume
77
Issue
1
Pages
17-25
ISSN
0026-895X
DOI
10.1124/mol.109.057877
Cited by
132
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.